脑脊液突触生物标志物组合用于预测阿尔茨海默病的突触通路解析
本研究为回顾性横断面单中心研究,纳入243例神经认知功能下降患者,评估脑脊液突触生物标志物(GAP-43、神经颗粒素、SNAP-25总、SNAP-25aa40、突触结合蛋白-1)组合区分阿尔茨海默病(AD)与非AD疾病的能力。结果显示所有突触标志物在MCI-AD和AD痴呆中显著升高,SNAP-25aa40鉴别能力最强(AD痴呆 vs 对照或OD的AUC为0.93,MCI-AD vs 对照的AUC为0.90)。
要点
- 脑脊液突触生物标志物在MCI-AD和AD痴呆中显著升高,可有效鉴别AD与非AD。
- SNAP-25aa40鉴别能力最高(AD痴呆 vs 对照或OD的AUC 0.93)。
- 较高突触标志物水平与APOE ε4双等位基因相关。
核心结论
- 所有检测的突触生物标志物均能较好区分AD脑脊液阳性患者与非AD疾病患者。
- SNAP-25aa40在本队列中区分AD脑脊液阳性患者与无AD患者及神经科对照的能力最高。
研究设计与样本
- 回顾性横断面单中心研究,纳入243例接受脑脊液评估的神经认知功能下降患者。
- 脑脊液突触标志物(GAP-43、神经颗粒素、SNAP-25总、SNAP-25aa40、突触结合蛋白-1)与AD标志物采用ELISA或质谱法盲法定量。
主要发现
- 所有突触生物标志物在MCI-AD和AD痴呆患者中较其他组显著升高。
- 所有突触标志物均可有效区分AD痴呆与其他痴呆(AUC≥0.80)。
- 除突触结合蛋白外,其余标志物可区分MCI-AD与对照(AUC≥0.85)及AD痴呆与对照(AUC≥0.80)。
- SNAP-25aa40鉴别能力最高:AD痴呆 vs 对照或OD的AUC为0.93,MCI-AD vs 对照的AUC为0.90。
- 较高突触标志物水平与APOE ε4双等位基因相关。
关键数值与推荐
- AD痴呆与其他痴呆鉴别:所有突触标志物AUC≥0.80。
- MCI-AD与对照鉴别:除突触结合蛋白外,AUC≥0.85。
- AD痴呆与对照鉴别:除突触结合蛋白外,AUC≥0.80。
- SNAP-25aa40:AD痴呆 vs 对照或OD的AUC为0.93;MCI-AD vs 对照的AUC为0.90。
临床怎么用
- 脑脊液突触生物标志物组合可用于辅助区分AD与非AD神经认知疾病。
- SNAP-25aa40可能作为鉴别AD脑脊液阳性患者的高效标志物。
局限性
- 本研究为回顾性横断面单中心研究,证据等级为Class II。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the ability of a combination of synaptic CSF biomarkers to separate Alzheimer disease (AD) and non-AD disorders and to help in the differential diagnosis between neurocognitive diseases. METHODS: This was a retrospective cross-sectional monocentric study. All participants explored with CSF assessments for neurocognitive decline were invited to participate. After complete clinical and imaging evaluations, 243 patients were included. CSF synaptic (GAP-43, neurogranin, SNAP-25 total, SNAP-25aa40, synaptotagmin-1) and AD biomarkers were blindly quantified with ELISA or mass spectrometry. Statistical analysis compared CSF levels between the various groups of AD dementias (n = 81), mild cognitive impairment (MCI)-AD (n = 30), other MCI (n = 49), other dementias (OD) (n = 49), and neurologic controls (n = 35) and their discriminatory powers. RESULTS: All synaptic biomarkers were significantly increased in patients with MCI-AD and AD-dementia compared to the other groups. All synaptic biomarkers could efficiently discriminate AD dementias from OD (AUC ≥0.80). All but synaptotagmin were also able to discriminate patients with MCI-AD from controls (area under the curve [AUC] ≥0.85) and those with AD dementias from controls (AUC ≥0.80). Overall, CSF SNAP-25aa40 had the highest discriminative power (AUC 0.93 between patients with AD dementias and controls or OD, AUC 0.90 between those with MCI-AD and controls). Higher levels were associated with 2 alleles of APOE ε4. CONCLUSION: All synaptic biomarkers tested had a good discriminatory power to distinguish patients with AD abnormal CSF from those with non-AD disorders. SNAP25aa40 demonstrated the highest power to discriminate AD CSF-positive patients from patients without AD and neurologic controls in this cohort. CLASSIFICATION OF EVIDENCE: This retrospective study provides Class II evidence that CSF synaptic biomarkers discriminate patients with AD from those without AD.
引用
- Tible M, Sandelius Å, Höglund K, et al. Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology. 2020. PMID: 32586895. doi:10.1212/WNL.0000000000010131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。